Sonoma Biotherapeutics
Leading the Next Frontier of Cell Therapy
Leading the Next Frontier of Cell Therapy
Sonoma BioTherapeutics is a biotechnology startup that is leading the next frontier of cell therapy. The company, founded in 2020, is focused on developing engineered regulatory T cell (Treg) therapies to address serious autoimmune and inflammatory diseases driven by an imbalanced immune system. With a team of pioneers in Treg biology and cell therapy, Sonoma BioTherapeutics is utilizing proprietary platform technologies and approaches to create a new generation of targeted Treg cell therapies. These therapies are designed to induce durable immune tolerance and effectively treat and prevent autoimmune and inflammatory diseases.
The startup, headquartered in South San Francisco and Seattle, recently secured a significant $30.00M corporate round investment on 28 March 2023, with Regeneron as one of the key investors.
With a focus on cutting-edge technology and a dedicated team, Sonoma BioTherapeutics is well-positioned to make a meaningful impact in the field of biotechnology and cell therapy, offering promising solutions for patients with autoimmune and inflammatory conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | $30.00M | 1 | Regeneron | 28 Mar 2023 |
| Series B | $265.00M | 9 |
|
04 Aug 2021 |
| Series A | $30.00M | - | 30 Sep 2020 | |
| Series A | $40.00M | - | 06 Feb 2020 |
No recent news or press coverage available for Sonoma Biotherapeutics.
We care about your data, and we'd love to use cookies make your experience better.
